Hormonotherapy of advanced prostate cancer-Reference-Cited by-同舟云学术

Hormonotherapy of advanced prostate cancer

Published:2005-05 Issue: Volume:16 Page:iv80-iv84
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Pronzato P.,Rondini M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/16/suppl_4/iv80/385376/mdi913.pdf

Reference21 articles.

1. The current state of hormonal therapy of Prostate Cancer;Hellerstedt;CA Cancer J Clin Oncol,2002

2. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer;Mc Donnell;Cancer Res,1992

3. Carcinoma of the prostate: Treatment comparisons;J Urol,1967

4. European Organisation for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976–1996;Denis;Urology,1998

5. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study;Potosky;J Clin Oncol,2001

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing of bioactive natural products in prostate cancer research and care: Promising discoveries and future directions;Intelligent Pharmacy;2024-07

2. Demethylase FTO inhibits the development of prostate cancer by upregulating EGR2 expression in an m6A manner;Turkish Journal of Biology;2022-01-01

3. Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo;Acta Pharmaceutica Sinica B;2017-01

4. Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer;World Journal of Urology;2011-12-23

5. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development;World Journal of Clinical Oncology;2011